-
Endothelial SGK1 Mediates Vascular Stiffening
2026-09-16
Zhang et al. identify endothelial SGK1 as a mechanistic link between mineralocorticoid–salt exposure, sodium-channel activity, actin remodeling, and vascular stiffening. By combining endothelial-specific genetics with pharmacological inhibition in human aortic endothelial cells, the study supports SGK1 as a target for mechanistic hypertension and vascular biology research.
-
Magnetic CAR-T-Mimicking Cells for Solid Tumors
2026-09-16
This Advanced Materials study introduces a magnetic bispecific nano-antibody that engages endogenous T cells in vivo and guides them into solid tumors with an external magnetic field. The approach addresses two major barriers to solid-tumor CAR-T therapy—limited tumor infiltration and local immunosuppression—without relying on conventional ex vivo cell manufacturing or genetic CAR insertion.
-
Proteinase K: A Selectivity Control for Protease Assays
2026-09-15
Proteinase K is more than a DNA preparation reagent: it is a broad-spectrum serine protease that can strengthen protease assay controls. This article connects genomic DNA isolation, enzyme contaminant removal, and SARS-CoV-2 3CLpro assay design through a selectivity-focused framework.
-
Alfuzosin HCl in Translational Urology
2026-09-15
A mechanistic and strategic guide to using Alfuzosin HCl in benign prostatic hyperplasia research, from α1-adrenergic biology and contractility assays to formulation, comparator selection, and translational interpretation.
-
Tivozanib (AV-951): A Smarter Assay Strategy
2026-09-14
Tivozanib (AV-951) is a highly selective VEGFR inhibitor with important implications for renal cell carcinoma treatment and translational assay design. This guide presents a pathway-to-phenotype workflow that separates target engagement, growth inhibition, and cell death for more reliable oncology research.
-
Eicosapentaenoic Acid (EPA) Workflow Guide
2026-09-14
Build reproducible EPA experiments around membrane remodeling, lipid oxidation, and endothelial migration rather than treating one dose as universally predictive. This workflow also shows how to use the recent arachidonic acid immunology study as a carefully bounded comparator for hypothesis generation, not as evidence that EPA is a vaccine adjuvant.
-
Estradiol, ER Signaling, and T-Cell Recovery After Shock
2026-09-13
The reference study shows that hemorrhagic shock suppresses splenic CD4+ T-lymphocyte function while increasing endoplasmic reticulum stress, and that 17β-estradiol reverses these changes through ERα- and GPR30-associated pathways. Its pharmacological design links estrogen signaling to ER-stress control, providing a useful mechanistic framework while remaining distinct from oncology applications of ICI 182,780.
-
Anlotinib Hydrochloride: From Target to Phenotype
2026-09-12
Anlotinib hydrochloride links VEGFR2, PDGFRβ, and FGFR1 inhibition to measurable anti-angiogenic phenotypes. This evidence-led guide explains how to design, interpret, and troubleshoot migration, tube formation, receptor phosphorylation, and ERK assays in cancer research.
-
Cy3 NHS Ester (Non-Sulfonated): Practical Guide
2026-09-12
Cy3 NHS ester (non-sulfonated) provides a reactive orange fluorophore for labeling primary amino groups in proteins, peptides, and oligonucleotides when an organic co-solvent is acceptable. It is not appropriate for water-only workflows or long-term storage of dye solutions, and delicate proteins may require a water-soluble sulfo-Cy3 alternative.
-
Novel Allosteric PDK4 Inhibitors for Metabolic Disease
2026-09-11
The reference study describes a medicinal-chemistry campaign that transformed an anthraquinone hit into allosteric pyruvate dehydrogenase kinase 4 inhibitors, led by compound 8c with an in vitro IC50 of 84 nM. Compound 8c also produced activity in mouse models of impaired glucose tolerance and allergic reactions, while cell studies suggested effects on cancer-related phenotypes, establishing a preclinical framework for PDH activation and metabolic disease research.
-
Decitabine: From DNMT1 Biology to Translation
2026-09-11
Decitabine (5-Aza-2'-deoxycytidine) is more than a DNA methyltransferase inhibitor: it is a dose-sensitive experimental system linking methylation loss, tumor suppressor gene reactivation, immune remodeling, and tolerability. This translational guide integrates mechanism, protocol design, murine toxicology, and strategic positioning for hematopoietic malignancy research and solid tumor epigenetic studies.
-
Amitriptyline HCl (B2231): Workflow & QC Guide
2026-09-10
Amitriptyline HCl (SKU B2231) provides a defined small-molecule reference for neurotransmitter receptor modulation, receptor profiling, and controlled neuropharmacology research. It is best used in freshly prepared, vehicle-controlled assays and should not be used to infer clinical efficacy, disease-model benefit, or long-term solution stability without independent validation.
-
Sulfo-Cy3 azide for Neurodevelopmental Imaging
2026-09-10
Sulfo-Cy3 azide combines water-compatible Click Chemistry fluorescent labeling with a bright Cy3 spectral profile for alkyne-tagged oligonucleotides, EdU, proteins, and intact samples. This article translates rat claustrum birth-dating findings into a practical workflow for spatial neurodevelopmental assays, with parameter screens and troubleshooting guidance.
-
DAMGO and the Circuit Logic of Opioid Pain
2026-09-09
A translational framework for using DAMGO to connect µ-opioid receptor pharmacology with brain–spinal circuit mechanisms of analgesia, mechanical hypersensitivity, and tolerance.
-
Cediranib (AZD2171): VEGFR Signaling Guide
2026-09-09
Cediranib, also called AZD2171, is an oral ATP-competitive VEGFR tyrosine kinase inhibitor used to study angiogenesis and tumor signaling. Its strongest biochemical activity is against VEGFR-2/KDR, while broader kinase activity and viability-readout limitations require careful experimental controls.